CURRICULUM VITAE

Prof. Adorni Maria Pia, PhD

PERSONAL DATA

Date of birth: June 11th, 1978
Place of birth: Parma, Italy
Nationality: Italian
Mailing address: University of Parma, Department of Medicine and Surgery, Unit of Neuroscience, Via Volturno 39/F, 43125 Parma, Italy
Email: mariapia.adorni@unipr.it

PROFSSIONAL PROFILE

Since 2025 Associate Professor of Pharmacology (BIOS-11/A) at the Department of Medicine and Surgery, University of Parma, Italy

RESEARCH CAREER

2022-2025 - Research Assistant Professor (RTD-B, BIO-14), Department of Medicine and Surgery, University of Parma, Parma Italy.
2020-2022 Post-doctoral Fellow, Department of Medicine and Surgery, University of Parma, Parma, Italy
2007-2019 Post-doctoral Fellow, Department of Food and Drug, University of Parma, Parma Italy;
2006-2007 PhD student, Children's Hospital of Philadelphia Research Institute, Philadelphia, USA, laboratory of lipid metabolism directed by Dr. Rothblat.
2003-2005 Research Fellowship, Department of Pharmacological and Biological Sciences and Applied Chemistry, University of Parma, Parma, Italy.

EDUCATION

2023 National scientific qualification to the role of Full Professor (GSD 05/BIOS-11 – Farmacologia).
2017 National scientific qualification to the role of Associate Professor (GSD 05/BIOS-11 – Farmacologia).
2007 Ph.D. in Experimental Pharmacology and Toxicology, University of Parma, Parma, Italy.
2003 MSc in Pharmaceutical Chemistry and Technology (110/110 cum Laude), University of Parma, Parma, Italy.

RESEARCH ACTIVITY

The research background focuses mainly on the investigation of mechanisms regulating lipid homeostasis and its modulation for the prevention and therapy of cardiovascular diseases and of other degenerative pathologies where cholesterol metabolism plays a role in the pathogenesis. These studies are performed mainly in vitro and ex vivo, by using cell-based assays and different techniques (radioisotopic, colorimetric, fluorimetric) and evaluating several cholesterol metabolism-related parameters, such as endogenous cholesterol synthesis, cholesterol uptake, distribution and the plasma membrane and efflux. Research activity also focuses on the study of plasma HDL functions, among which their capacity to promote cholesterol efflux, the anti-inflammatory and anti-oxidant activity, as index of HDL function, and their changes in several clinical conditions associated to higher cardiovascular risk, or after pharmacological or nutraceutical treatment. Recently, the research interest has moved to the study of lipid metabolism and its potential alterations in Alzheimer's disease and other degenerative pathologies in the search of novel lipid-based pharmacological targets.

HONORS

2016 - Grant for the best oral communication entitled "Pcsk9 inhibits the ABCA1 protein expression and cholesterol efflux from macrophages". XVI CONGRESSO della Società Italiana per lo studio dell'Aterosclerosi (SISA) REGIONALE EMILIA ROMAGNA (Parma, Italia).

2013- Grant for the best oral communication entitled "Evaluation Of Serum Cholesterol Efflux Capacity In Diabetics Compared To Healthy Subjects". 36 Congresso Nazionale della Società Italiana di Farmacologia (SIF) (Torino, Italia).

2010 - Grant for the "Young Investigator Poster Award"with the abstract entitled "MODULATION OF CELLULAR CHOLESTEROL EFFLUX PATHWAYS BY DIFFERENT PROBUCOL-LIKE ANALOGUES". 6th International Atherosclerosis Society-Sponsored Workshop on High Density Lipoproteins (Whistler, BC, Canada).

2009 - Grant for the "Young Investigator Poster Award" with the abstract entitled "ABCA1 modulates cellular migration and membrane ruffling induced by free cholesterol in macrophages foam cells". 15th ANNUAL SCANDINAVIAN ATHEROSCLEROSIS CONFERENCE (Copenhagen, Denmark).

2007- Grant for the best oral communication entitled "The roles of different pathways in the release of cholesterol from macrophages. VII CONGRESSO SISA REGIONALE EMILIA ROMAGNA (Parma, Italy).

2006 - "Honourable Mention" in the "Young Investigator Poster Award" with the abstract entitled "Cholesterol efflux from oxidized LDL loaded macrophages". XIV International Symposium on ATHEROSCLEROSIS (Roma, Italy).

2005- Grant "Astra Zeneca" for the best oral communication entitled "Cholesterol efflux potential of sera from subjects with LCAT deficiency". XIX CONGRESSO NAZIONALE SISA (Venezia Mestre, Italy).

MEMBERSHIPS

Member of the Italian Society of Pharmacology (SIF), the Italian Society of Atherosclerosis (SISA), the International Society of Arteriosclerosis (ISA), the European Atherosclerosis Society (EAS) and the European Lipoprotein Club (ELC).

MEETINGS

Maria Pia participated at several national and international scientific meetings with both poster and oral presentations and invited oral lectures or as chairman.

INTERNATIONAL MEETINGS

Invited oral presentations and oral communications

2020. 88th EAS Congress, Virtual Congress. Sex hormones therapy differentially modulates HDL function in transgender individuals. In: AtherosclerosisVol. 315e10Published in issue: December 2020

Comunicazione orale

2017. Giornata della Ricerca del Centro E. Grossi Paoletti: "Lipoproteins and dyslipidemias", Milano, Italy. Nutraceuticals and cholesterol trafficking

Relazione su invito

2010. III Workshop on Lipid Metabolism and Vascular Biology, Karolinska Institutet - University of Parma-Stoccolma, Svezia. Selective modulation of cellular cholesterol efflux pathways

Relazione su invito

2008. 31st Annual Meeteing EUROPEAN LIPOPROTEIN CLUB, Tutzing Germany. Probucol abolishes membrane ruffling and restores cellular migration in macrophages foam cells.

Comunicazione orale

2007. II WORKSHOP ON LIPID METABOLISM AND VASCULAR BIOLOGY, Karolinska Institutet - University of Parma, Parma, Italia. The relative contributions of pathways for efflux of cholesterol from macrophages

Relazione su invito

2005. I Workshop on Lipid Metabolism and Vascular Biology, Karolinska Institutet - University of Parma, Stoccolma, Svezia. Genetic and physiological determinants of reverse cholesterol transport

Relazione su invito

NATIONAL MEETINGS
Invited oral presentations and oral communications

2024. CONGRESSO REGIONALE SEZIONE TOSCO-EMILIANA, Arezzo, Italia
Dibattito sul tema “Metabolismo lipidico e neurodegenerazione”
Relazione su invito
2023. CONGRESSO REGIONALE SEZIONE TOSCO-EMILIANA, Bologna, Italia
Dibattito sul tema dei nuovi marcatori di rischio cardiovascolare: Il ruolo del trasporto inverso del colesterolo
Relazione su invito
2021. 40° CONGRESSO NAZIONALE della SOCIETÀ ITALIANA di FARMACOLOGIA, DIGITAL EDITION
Hormone treatment impacts on high density lipoprotein function in transgender people
Comunicazione orale
2019. CONVEGNO MONOTEMATICO della Società Italiana di Farmacologia (SIF) -Le basi farmacologiche dei Nutraceutici, Napoli, Italia.
Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9.
Comunicazione orale
2018. 32° Congresso Nazionale della Società Italiana per lo Studio dell'Arteriosclerosi (SISA) Bologna, Italia
Effect of JAK/STAT inhibition on macrophage cholesterol metabolism and atherosclerosis
Relazione su invito
2018. XVIII Congresso Regionale Società Italiana per lo Studio dell'Arteriosclerosi SISA sezione Emilia-Romagna, Bologna Italia.
Non solo riduzione della lipidemia: gli effetti pleiotropici di PCSK9
Relazione su invito
2016. 30° Convegno Nazionale della Società Italiana per lo studio dell’Aterosclerosi (SISA) Roma, Italia
Modulazione dell’omeostasi del colesterolo da parte di proprotein convertase subtilisin/kexin type 9 (pcsk9) nel macrofago. In: Giornale Italiano dell'Arteriosclerosi 2016;7(4):87-143
Comunicazione orale. Vince il Travel Grant
2016. Convegno regionale della Società Italiana per lo studio dell’Aterosclerosi (SISA) sezione Emilia-Romagna, Parma, Italia
Modulazione dell’omeostasi del colesterolo da parte di proprotein convertase subtilisin/kexin type 9 (pcsk9) nel macrofago
Comunicazione orale. Vince il Travel Grant
2014. 28° Congresso Nazionale della Società Italiana per lo Studio dell'Arteriosclerosi (SISA) Roma, Italia.
Impaired HDL cholesterol efflux capacity during development of pacing-induced heart failure in minipig.
In: Giornale Italiano dell'Arteriosclerosi 2014;5(4):65-119
Comunicazione orale. Vince il Travel Grant
2014. Congresso Regionale Società Italiana Studi sull’Aterosclerosi (SISA), Sezione Emilia Romagna, Modena, Italia. Metabolismo del colesterolo e macrofagi
Relazione su invito
2013. 27° Congresso Nazionale della Società Italiana per lo Studio dell'Arteriosclerosi (SISA) Roma, Italia
Pharmacological, atp-binding cassette transporter a1 (abca1)-dependent membrane free cholesterol pool reduction leads to atheroprotective modulation of macrophage functions.
In: Giornale Italiano dell'Arteriosclerosi 2013;4(4):73-126
Comunicazione orale. Vince il Travel Grant
2013. 36o Congresso Nazionale della Società Italiana di Farmacologia Torino, Italia
Evaluation Of Serum Cholesterol Efflux Capacity in Diabetic Compared To Healty Subjects
Comunicazione orale
2012. 1st SIRC Workshop on New Roads in Cardiovascular Research, Milano Italia
Serum cholesterol efflux capacity inversely correlates with arterial stiffness in healthy subjects.
Comunicazione orale
2012. XII Congresso Regionale Società Italiana Studi sull’Aterosclerosi (SISA), Sezione Emilia-Romagna Ravenna, Italia
Serum cholesterol efflux capacity inversely correlates with arterial stifness in healty subjects.

Comunicazione orale
2010. Congresso Regionale Società Italiana Studi sull'Aterosclerosi (SISA), Sezione Emilia-Romagna, Bologna Italia.
L'aterosclerosi la base della patologia e il ruolo dei due principali fattori di rischio: lipidi e ipertensione.
ABCA1 media gli effetti dell'accumulo di colesterolo sul ruffling di membrana e sulla migrazione nei macrofagi attraverso una via Rac-dipendente
Comunicazione orale
2010. XXIV Congresso Nazionale della Società Italiana per lo Studio dell'Arteriosclerosi (SISA) Roma, Italia.
Effect of the lipid lowering drug Berberine on the ABCA1- and ABCG1-mediated cholesterol efflux.
In: Giornale Italiano dell'Arteriosclerosi, Anno 1, N.0/2010.
Comunicazione orale. Vince il Travel Grant
2008. VIII Giornata di Studio "Ricerca clinica e di base nell'area cardiovascolare". SISA Regionale Lombardia, Milano, Italia
ABCA1 modula la migrazione cellulare e il ruffling di membrana indotto dal colesterolo libero in macrofagi foam cells
Comunicazione orale
2008. VIII Congresso Regionale Società Italiana Studi sull'Aterosclerosi (SISA), Sezione Emilia-Romagna "Novità nel campo dell'Aterosclerosi: dalla scienza di base alla prevenzione", Modena Italia.
Effetto della composizione delle HDL nel modulare l'efflusso di colesterolo attraverso i diversi meccanismi
Comunicazione orale
2007. VII Congresso Regionale Società Italiana Studi sull'Aterosclerosi (SISA), Sezione Emilia-Romagna "IL RISCHIO CARDIOVASCOLARE: NUOVE ACQUISIZIONI E PROSPETTIVE", Parma Italia.
Contributo dei diversi meccanismi di efflusso di colesterolo da macrofagi al siero umano
Comunicazione orale
2007. XXI Congresso Nazionale della Società Italiana per lo Studio dell'Arteriosclerosi (SISA), Perugia Italia
The relative contributions of pathways for efflux of cholesterol from macrophages
Comunicazione orale
2005. XVIII Congresso Nazionale della Società Italiana di Farmacologia (SIF), Napoli Italia
Lercanidipine Reduces Free Cholesterol-Induced Cytotoxicity
Comunicazione orale
2005. XIX Congresso Nazionale della Società Italiana per lo Studio dell'Arteriosclerosi (SISA), Venezia Mestre Italia.
Cholesterol efflux potential of sera from subjects with LCAT deficiency
Comunicazione orale
2005. VII Congresso Regionale Società Italiana Studi sull'Aterosclerosi (SISA), Sezione Emilia-Romagna, Ferrara Italia
Modulazione del processo di efflusso di colesterolo nei macrofagi
Comunicazione orale
2004. XI Congresso Nazionale della Società Italiana di Ricerche Cardiovascolari (SIRC), Latina Italia
La lercanidipina riduce la tossicita' cellulare indotta dall'accumuolo di colesterolo libero
Comunicazione orale
2004. XVIII Congresso Nazionale della Società Italiana per lo Studio dell'Arteriosclerosi (SISA), Palermo Italia
Lercanidipine Reduces Free Cholesterol-Induced Cytotoxicity
Comunicazione orale

Participation as chairman

2019. XIX Congresso Regionale SISA Sezione Emilia-Romagna "Aterosclerosi tra lipoproteine infiammazione e microbiota: conferme e prospettive", Bologna.2018. XVIII Congresso regionale SISA sezione Emilia-Romagna "Aterosclerosi e malattie cardiovascolari:
aspetti innovativi nel campo della ricerca e della gestione clinica", Modena.

EDITORIAL ACTIVITY

From 2024. Member of the Editorial Board of the Journal Lipidology (https://www.mdpi.com/journal/lipidology/editors)

2025-2026. Guest Editor for the Special Issue “Lipid Metabolism and Inflammation-Related Diseases”, Lipidology (ISSN: 2813-7086

2022-2023. Guest Editor for the Special Issue “Pharmacological Lipid Strategies for Cardiovascular Disease Prevention: Part II”, Journal of Clinical Medicine (ISSN 2077-0383).

2020-2021. Guest Editor for the Special Issue "Nutrition Intervention and Cardiovascular Disease", Nutrients (ISSN 2072-6643).

From 2017. Reviewer of scientific articles for the following international journals:

Medicine, PlosOne, Atherosclerosis, Atherosclerosis Plus, Nutrition Metabolism and Cardiovascular disease (NMCD), Frontiers in Paharmacology, British Journal of Nutrition, Scientific Reports, Pharmaceutics, International Journal of Molecular Sciences, European Journal of Pharmacology, The Journal of Clinical Endocrinology & Metabolism, Lipids in Health and Disease, Cellular Signaling, Cellular and Molecular Life Sciences.

MEETING ORGANIZATION

2023 Member of the local committee for the organization of the monothematic congress of the Italian Society of Pharmacology (SIF) Le basi molecolari della farmacologia cardiometabolica: cross talk tra cuore, vasi e metabolism, Parma (Italy), october 16-17.

2018 Member of the Scientific and local committee for the organization of the IV Whorkshop on Lipid Metabolism and Vascular Biology, University of Parma - Karolinska Institutet, Parma (Italy), October 8-10.

PROJECTS

2024 Project funded as part of the 2024 University Call for Research, line B, entitled "Exploring the relationship between cholesterol metabolism and vascular senescence: potential new target in aging-associated cardiovascular diseasses". Role in the project: Principal-investigator

2024. Participation in the scientific project in the context of del PNRR, Cascata Call for Extended Partnership Foundation IN-FACT One Health Basic and Translational Actions Addressing Unmet Needs on Emerging Infectious Diseases, Node 5 MEDICINAL CHEMISTRY TECHNOLOGIES FOR THE DEVELOPMENT OF INNOVATIVE ANTIVIRALS, titolo Preparedness Against Newly-emerging Viruses: Innovations in Research, Intervention, and Drug Evolution (PANVIRIDE). Role: Co-investigator

2022. Funding obtained as part of the University Call for the acquisition of research equipment (art. 2 of MUR decree no. 737 of 25/06/2021) for the purchase of a liquid phase scintillation meter for the detection of beta emissions. Role: Co-proponent

2019. Participation in the scientific project funded by Amgen Inc. (PCSK9 Competitive Grant Program) Titolo: EXplorIng the paThophysological role of PCSK9 in Alzheimer’s Disease: focus on inflammation and lipid metabolism (EXIT-AD). Role: Co-Investigator.

2016. Participation in the scientific research project funded by Aegerion Pharmaceuticals SARL. Title: Evaluation of LOMITAPIDE treatment on affecting HDL functionality of serum from patients with homozygous familial hypercholesterolemia. Role: Co-Investigator.

2013. Participation in the scientific project funded by Rottapharm s.p.a. Title: ""In vivo effects of red yeast, policosanols and berberine on the antiatherogenic process of reverse cholesterol transport and systemic inflammation. Role: Co-investigator

2012. Participation in the national research project funded by Fondazione Cariplo as part of the call "Scientific Research in the Biomedical field-2012". Title: Investigating the role of pro-protein convertase subtilisin/kexin type 9 (PCSK9) released from smooth muscle cells on atherogenesis, (Grant Ref. 2012-0549).
Role: fallow to carry out the research activity related to the project

2011. Participation in the research project funded by the Ministry of Health (Call 2011-2012/Young Researchers). Title: Targeting inflammation in atherosclerosis: role and therapeutic potential of sphingosine 1- phosphate (S1P) and its receptors, (Grant GR-2011-02346974).
Role: holder of a research grant to carry out the research activity related to the project

2009. Participation in the national research project funded by Fondazione Cariplo (Call for Scientific Research in the Biomedical field 2009). Title: HDL quantity or quality to improve cardiovascular prevention: insights from inherited HDL disorders, (Grant Rif. 2009-20576). Role: Co-Investigator
2007-2009. Participation in the regional project "DiAL-ER/ADSL: Advanced Diagnostic Support in Lipdology: within the Regional Program "Research Region-University 2007-2009. Title: Role of genotypic, phenotypic and functional evaluation of lipoproteins in dyslipidemias.
Role: fellow to carry out the research activity related to the project

PUBLICATIONS

Maria Pia Adorni is author of 76 peer reviewed-publications
H-INDEX: 28 (Scopus)
Total citations: 2813(Scopus)
Citations/publication: 37.5
Total Impact Factor (IF): 378
Mean IF: 5.1

LIST OF PUBLICATIONS

Divergent regulation of cellular cholesterol metabolism by seaweed-derived fucosterol and saringosterol.
Na Zhan, Nikita Martens, Yanlin Li, Gardi Voortman, Frank Leijten, Silvia Friedrichs, Martien P. M. Caspers, Lars Verschuren, Tim Vanmierlo, Marieke Smit, Folkert Kuipers, Johan W. Jonker, Vincent W. Bloks, Marcella Palumbo, Francesca Zimetti, Maria Pia Adorni, Hongbing, Dieter Lütjohann and Monique T. Mulder
Frontiers in Marine Science, Sec. Marine Biotechnology and Bioproducts, Volume 12 2025, doi.org/10.3389/fmars.2025.1728727 2025, 12.

Mechanisms, Mediators, and Pharmacological Approaches Targeting Brain Cholesterol Transport in Alzheimer's Disease.
Ugolotti M, Papotti B, Trentini A, Mola G, Cervellati C, Adorni MP*, Zimetti F*.
Curr Pharm Des. 2025 Oct 1. doi: 10.2174/0113816128411158250909151734.

Anti-atherosclerotic effects of natural compounds targeting lipid metabolism and inflammation: Focus on PPARs, LXRs, and PCSK9. Review
M. Palumbo, M. Ugolotti, F. Zimetti, M.P. Adorni*. Atherosclerosis Plus. Volume 59, March 2025, Pages 39-53. doi: 10.1016/j.athplu.2024.12.004.
*corresponding author

Changes in serum cholesterol loading capacity are linked to coronary atherosclerosis progression in rheumatoid arthritis.
Karpouzas GA, Papotti B, Ormseth SR, Palumbo M, Hernandez E, Adorni MP, Zimetti F, Ronda N. RMD Open.24;10(4):e004991. doi: 10.1136/rmdopen-2024-004991.

Influence of APOE4 genotype on PCSK9-lipids association in cerebrospinal fluid and serum of patients in the Alzheimer's disease continuum.
Papotti B, Palumbo M, Adorni MP, Elviri L, Chiari A, Tondelli M, Bedin R, Baldelli E, Lancellotti G, Lupo MG, Ferri N, Bertolotti M, Bernini F, Mussi C, Zimetti F.J Alzheimers Dis. 2024 Nov;102(1):162-172. doi: 10.1177/13872877241284213.

HDL cholesterol efflux capacity and cholesterol loading capacity in long-term fasting: Evidence from a prospective, single-arm interventional study in healthy individuals.
Grundler F, Palumbo M, Adorni MP, Zimetti F, Papotti B, Plonné D, Holley A, Mesnage R, Ruscica M, Wilhelmi de Toledo F. Atherosclerosis. 2024 Oct;397:118548. doi: 10.1016/j.atherosclerosis.2024.118548.

Bioactive alkaloids from Nepalese Corydalis chaerophylla D.C. acting on the regulation of PCSK9 and LDL-R in vitro.
Maharjan B, Rossi I, Sut S, Shrestha T, Shrestha LK, Hill JP, Ariga K, Benetazzo V, Adorni MP, Papotti B, Shrestha SS, Shrestha RLS, Ferri N, Dall'Acqua S.
Chem Biodivers. 2024 Jul 27:e202401388. doi: 10.1002/cbdv.202401388.

Gene Silencing of Angiopoietin-like 3 (ANGPTL3) Induced De Novo Lipogenesis and Lipid Accumulation in Huh7 Cell Line.
Rossi I, Marodin G, Lupo MG, Adorni MP, Papotti B, Dall'Acqua S, Ferri N.
Int J Mol Sci. 2024 Mar 26;25(7):3708. doi: 10.3390/ijms25073708.

In vitro evaluation of the immunomodulatory activity of the nutraceutical formulation AminoDefence.
Papotti B, Dessena M, Adorni MP, Paleari D, Rinaldi L, Bernini F.
Int J Food Sci Nutr. 2024 Mar;75(2):173-184. doi: 10.1080/09637486.2023.2283688.
*corresponding author

Cyclic fasting bolsters cholesterol biosynthesis inhibitors' anticancer activity.
Khalifa A, Guijarro A, Ravera S, Bertola N, Adorni MP, Papotti B, Raffaghello L, Benelli R, Becherini P, Namatalla A, Verzola D, Reverberi D, Monacelli F, Cea M, Pisciotta L, Bernini F, Caffa I, Nencioni A.
Nat Commun. 2023 Oct 31;14(1):6951. doi: 10.1038/s41467-023-42652-1.

Effect of the JAK/STAT Inhibitor Tofacitinib on Macrophage Cholesterol Metabolism.
Adorni MP, Papotti B, Borghi MO, Raschi E, Zimetti F, Bernini F, Meroni PL, Ronda N.
Int J Mol Sci. 2023 Aug 8;24(16):12571. doi: 10.3390/ijms241612571.

Effects of Handroanthus impetiginosus (Mart. ex DC.) Mattos extract on inflammatory, immune, atherogenic profile and differentiation in THP-1 cell line.
Rossi I, Barollo S, Bertazza L, Mondin A, Pedron MC, Marodin G, Lupo MG, Palumbo M, Adorni MP, Mian C, Pezzani R, Ferri N.
Nat Prod Res. 2023 Aug 7:1-6. doi: 10.1080/14786419.2023.2244125.

Inflammation and immunomodulatory therapies influence the relationship between ATP-binding cassette A1 membrane transporter-mediated cholesterol efflux capacity and coronary atherosclerosis in rheumatoid arthritis.
Karpouzas GA, Papotti B, Ormseth SR, Palumbo M, Hernandez E, Adorni MP, Zimetti F, Budoff MJ, Ronda N.
J Transl Autoimmun. 2023 Jul 18;7:100209. doi: 10.1016/j.jtauto.2023.100209.

Statins influence the relationship between ATP-binding cassette A1 membrane transporter-mediated cholesterol efflux capacity and coronary atherosclerosis in rheumatoid arthritis.
Karpouzas GA, Papotti B, Ormseth SR, Palumbo M, Hernandez E, Adorni MP, Zimetti F, Budoff MJ, Ronda N.
J Transl Autoimmun. 2023 Jul 7;7:100206. doi: 10.1016/j.jtauto.2023.100206.

Hydroxypropyl-β-Cyclodextrin Depletes Membrane Cholesterol and Inhibits SARS-CoV-2 Entry into HEK293T-ACEhi Cells.
Alboni S, Secco V, Papotti B, Vilella A, Adorni MP, Zimetti F, Schaeffer L, Tascedda F, Zoli M, Leblanc P, Villa E.
Pathogens. 2023 Apr 27;12(5):647. doi: 10.3390/pathogens12050647.

ATP-binding cassette G1 membrane transporter-mediated cholesterol efflux capacity influences coronary atherosclerosis and cardiovascular risk in Rheumatoid Arthritis.
Karpouzas GA, Papotti B, Ormseth SR, Palumbo M, Hernandez E, Adorni MP, Zimetti F, Budoff MJ, Ronda N.
J Autoimmun. 2023 Apr;136:103029. doi: 10.1016/j.jaut.2023.103029.

Identification of Side Chain Oxidized Sterols as Novel Liver X Receptor Agonists with Therapeutic Potential in the Treatment of Cardiovascular and Neurodegenerative Diseases.
Zhan N, Wang B, Martens N, Liu Y, Zhao S, Voortman G, van Rooij J, Leijten F, Vanmierlo T, Kuipers F, Jonker JW, Bloks VW, Lütjohann D, Palumbo M, Zimetti F, Adorni MP, Liu H, Mulder MT.
Int J Mol Sci. 2023 Jan 9;24(2):1290. doi: 10.3390/ijms24021290.

A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC.
Adorni MP, Galetti M, La Monica S, Incerti M, Ruffoni A, Elviri L, Zanotti I, Papotti B, Cavallo D, Alfieri R, Petronini PG, Bernini F.
Int J Mol Sci. 2023 Jan 4;24(2):989. doi: 10.3390/ijms24020989.

Role of Lipoprotein Levels and Function in Atherosclerosis Associated with Autoimmune Rheumatic Diseases.
Ronda N, Zimetti F, Adorni MP, Palumbo M, Karpouzas GA, Bernini F.
Rheum Dis Clin North Am. 2023 Feb;49(1):151-163. doi: 10.1016/j.rdc.2022.07.006. Review.

PCSK9 Confers Inflammatory Properties to Extracellular Vesicles Released by Vascular Smooth Muscle Cells.
Greco MF, Rizzuto AS, Zarà M, Cafora M, Favero C, Solazzo G, Giusti I, Adorni MP, Zimetti F, Dolo V, Banfi C, Ferri N, Sirtori CR, Corsini A, Barbieri SS, Pistocchi A, Bollati V, Macchi C, Ruscica M.
Int J Mol Sci. 2022 Oct 28;23(21):13065. doi: 10.3390/ijms232113065.

PCSK9 Affects Astrocyte Cholesterol Metabolism and Reduces Neuron Cholesterol Supplying In Vitro: Potential Implications in Alzheimer's Disease.
Papotti B, Adorni MP, Marchi C, Zimetti F, Ronda N, Panighel G, Lupo MG, Vilella A, Giuliani D, Ferri N, Bernini F.
Int J Mol Sci. 2022 Oct 13;23(20):12192. doi: 10.3390/ijms232012192.

HDL metabolism and functions impacting on cell cholesterol homeostasis are specifically altered in patients with abdominal aortic aneurysm.
Adorni MP, Palumbo M, Marchi C, Zimetti F, Ossoli A, Turri M, Bernini F, Hollan I, Moláček J, Treska V, Ronda N.
Front Immunol. 2022 Sep 12;13:935241. doi: 10.3389/fimmu.2022.935241.

Serum cholesterol loading capacity on macrophages is linked to coronary atherosclerosis and cardiovascular event risk in rheumatoid arthritis.
Karpouzas GA, Papotti B, Ormseth S, Palumbo M, Hernandez E, Adorni MP, Zimetti F, Budoff M, Ronda N.
RMD Open. 2022 Sep;8(2):e002411. doi: 10.1136/rmdopen-2022-002411.

Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation.
Palumbo M, Giammanco A, Purrello F, Pavanello C, Mombelli G, Di Pino A, Piro S, Cefalù AB, Calabresi L, Averna M, Bernini F, Zimetti F, Adorni MP*, Scicali R*.
Front Mol Biosci. 2022 Jul 19;9:925587. doi: 10.3389/fmolb.2022.925587.
*co-last authors

HDL Cholesterol Efflux and Serum Cholesterol Loading Capacity Alterations Associate to Macrophage Cholesterol Accumulation in FH Patients with Achilles Tendon Xanthoma.
Adorni MP, Biolo M, Zimetti F, Palumbo M, Ronda N, Scarinzi P, Simioni P, Lupo MG, Ferri N, Previato L, Bernini F, Zambon A.
Int J Mol Sci. 2022 Jul 26;23(15):8255. doi: 10.3390/ijms23158255.

Nutrition Intervention and Cardiovascular Disease.
Adorni MP, Ferri N.

Nutrients. 2022 Mar 30;14(7):1435. doi: 10.3390/nu14071435.

Emerging role of HDL in brain cholesterol metabolism and neurodegenerative disorders.
Turri M, Marchi C, Adorni MP, Calabresi L, Zimetti F.
Biochim Biophys Acta Mol Cell Biol Lipids. 2022 Feb 10:159123. doi: 10.1016/j.bbalip.2022.159123

HDL in COVID-19 Patients: Evidence from an Italian Cross-Sectional Study.
Papotti B, Macchi C, Favero C, Iodice S, Adorni MP, Zimetti F, Corsini A, Aliberti S, Blasi F, Carugo S, Bollati V, Vicenzi M, Ruscica M.
J Clin Med. 2021 Dec 18;10(24):5955. doi: 10.3390/jcm10245955.

Drug drug interactions in polypharmacy patients: The impact of renal impairment".
Papotti B., Marchi C., Adorni MP*, Potì F.
Current Research in Pharmacology and Drug Discovery. 2021 Mar 29:2:100020. doi: 10.1016/j.crphar.2021.100020.
*corresponding author

Pcsk9 induces rat smooth muscle cell proliferation and counteracts the pleiotropic effects of simvastatin
Lupo, M.G., Marchianò, S., Adorni, MP, Zimetti F., Ruscica M., Greco M.F., Corsini, A., Ferri, N.
Int J Mol Sci. 2021 Apr 16;22(8):4114. doi: 10.3390/ijms22084114.

The effect of transgender hormonal treatment on high density lipoprotein cholesterol efflux capacity.
van Velzen DM*, Adorni MP*, Zimetti F, Strazzella A, Simsek S, Sirtori CR, Heijer MD, Ruscica M.
Atherosclerosis. 2021 Apr;323:44-53. doi: 10.1016/j.atherosclerosis.2021.03.008.
*co-first author

High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives.
Adorni MP, Ronda N, Bernini F, Zimetti F.
Cells. 2021 Mar 5;10(3):574. doi: 10.3390/cells10030574.

Cardiovascular risk and testosterone - from subclinical atherosclerosis to lipoprotein function to heart failure.
Gencer B, Bonomi M, Adorni MP, Sirtori CR, Mach F, Ruscica M.
Rev Endocr Metab Disord. 2021 Jun;22(2):257-274. doi: 10.1007/s11154-021-09628-2.

Connection between the Altered HDL Antioxidant and Anti-Inflammatory Properties and the Risk to Develop Alzheimer's Disease: A Narrative Review.
Zimetti F, Adorni MP*, Marsillach J, Marchi C, Trentini A, Valacchi G, Cervellati C.
Oxid Med Cell Longev. 2021 Jan 8;2021:6695796. doi: 10.1155/2021/6695796.
*corresponding author

HDL Proteome and Alzheimer's Disease: Evidence of a Link.
Marsillach J, Adorni MP, Zimetti F, Papotti B, Zuliani G, Cervellati C.
Antioxidants (Basel). 2020 Dec 3;9(12):1224. doi: 10.3390/antiox9121224.

Anti-atherogenic Modification of Serum Lipoprotein Function in Patients with Rheumatoid Arthritis after Tocilizumab Treatment, a Pilot Study.
Greco D, Gualtierotti R, Agosti P, Adorni MP, Ingegnoli F, Rota M, Bernini F, Meroni PL, Ronda N.
J Clin Med. 2020 Jul 8;9(7):2157. doi: 10.3390/jcm9072157.

Functional pasta consumption in healthy volunteers modulates ABCG1-mediated cholesterol efflux capacity of HDL.
Favari E, Angelino D, Cipollari E, Adorni MP, Zimetti F, Bernini F, Ronda N, Pellegrini N.

Nutr Metab Cardiovasc Dis. 2020 Sep 24;30(10):1768-1776. doi: 10.1016/j.numecd.2020.05.002.

Naturally Occurring PCSK9 Inhibitors.
Adorni MP, Zimetti F, Lupo MG, Ruscica M, Ferri N.
Nutrients. 2020 May 16;12(5):1440. doi: 10.3390/nu12051440.

Cholesterol-Lowering Action of a Novel Nutraceutical Combination in Uremic Rats: Insights into the Molecular Mechanism in a Hepatoma Cell Line.
Lupo MG, Biancorosso N, Brilli E, Tarantino G, Adorni MP, Vivian G, Salvalaio M, Dall'Acqua S, Sut S, Neutel C, Chen H, Bressan A, Faggin E, Rattazzi M, Ferri N.
Nutrients. 2020 Feb 9;12(2):436. doi: 10.3390/nu12020436.

Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia.
Ruscica M, Zimetti F, Adorni MP, Sirtori CR, Lupo MG, Ferri N.
Pharmacol Res. 2020 Mar;153:104653. doi: 10.1016/j.phrs.2020.104653.

Infusions of Large Synthetic HDL Containing Trimeric apoA-I Stabilize Atherosclerotic Plaques in Hypercholesterolemic Rabbits.
Parolini C, Adorni MP, Busnelli M, Manzini S, Cipollari E, Favari E, Lorenzon P, Ganzetti GS, Fingerle J, Bernini F, Chiesa G.
Can J Cardiol. 2019 Oct;35(10):1400-1408. doi: 10.1016/j.cjca.2019.05.033.

Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer's Disease.
Adorni MP, Ruscica M, Ferri N, Bernini F, Zimetti F.
Front Aging Neurosci. 2019 May 22;11:120. doi: 10.3389/fnagi.2019.00120.

ABCA1- and ABCG1-mediated cholesterol efflux capacity of cerebrospinal fluid is impaired in Alzheimer's disease.
Marchi C*, Adorni MP*, Caffarra P, Ronda N, Spallazzi M, Barocco F, Galimberti D, Bernini F, Zimetti F.
J Lipid Res. 2019 Aug;60(8):1449-1456. doi: 10.1194/jlr.P091033.
*co-first author

Activation profiles of monocyte-macrophages and HDL function in healthy women in relation to menstrual cycle and in polycystic ovary syndrome patients.
Tedesco S*, Adorni MP*, Ronda N, Cappellari R, Mioni R, Barbot M, Pinelli S, Plebani M, Bolego C, Scaroni C, Bernini F, Fadini GP, Cignarella A.
Endocrine. 2019 Nov;66(2):360-369. doi: 10.1007/s12020-019-01911-2.
*co-first author

High-Density Lipoprotein Function Is Reduced in Patients Affected by Genetic or Idiopathic Hypogonadism.
Adorni MP, Zimetti F, Cangiano B, Vezzoli V, Bernini F, Caruso D, Corsini A, Sirtori CR, Cariboni A, Bonomi M, Ruscica M.
J Clin Endocrinol Metab. 2019 Aug 1;104(8):3097-3107. doi: 10.1210/jc.2018-02027.

Vitamin D replacement ameliorates serum lipoprotein functions, adipokine profile and subclinical atherosclerosis in pre-menopausal women.
Greco D, Kocyigit D, Adorni MP, Marchi C, Ronda N, Bernini F, Gurses KM, Canpinar H, Guc D, Oguz SH, Gurlek A, Strazzella A, Simonelli S, Tokgozoglu L, Zimetti F.
Nutr Metab Cardiovasc Dis. 2018 Aug;28(8):822-829. doi: 10.1016/j.numecd.2018.04.010.

Cholesterol efflux capacity does not associate with coronary calcium, plaque vulnerability, and telomere length in healthy octogenarians.
Zimetti F, Freitas WM, Campos AM, Daher M, Adorni MP, Bernini F, Sposito AC, Zanotti I; Brazilian Study on Healthy Aging.
J Lipid Res. 2018 Apr;59(4):714-721. doi: 10.1194/jlr.P079525.

PCSK9 induces a pro-inflammatory response in macrophages.
Ricci C, Ruscica M, Camera M, Rossetti L, Macchi C, Colciago A, Zanotti I, Lupo MG, Adorni MP, Cicero AFG, Fogacci F, Corsini A, Ferri N.
Sci Rep. 2018 Feb 2;8(1):2267. doi: 10.1038/s41598-018-20425-x.

Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9.
Adorni MP, Ferri N, Marchianò S, Trimarco V, Rozza F, Izzo R, Bernini F, Zimetti F.
Ther Clin Risk Manag. 2017 Dec 11;13:1555-1562. doi: 10.2147/TCRM.S144121.

Plasma cholesterol homeostasis, HDL remodeling and function during the acute phase reaction.
Zimetti F, De Vuono S, Gomaraschi M, Adorni MP, Favari E, Ronda N, Ricci MA, Veglia F, Calabresi L, Lupattelli G.
J Lipid Res. 2017 Oct;58(10):2051-2060. doi: 10.1194/jlr.P076463.

Analysis of Serum Cholesterol Efflux Capacity in a Minipig Model of Nonischemic Heart Failure.
Bigazzi F*, Adorni MP*, Puntoni M, Sbrana F, Lionetti V, Pino BD, Favari E, Recchia FA, Bernini F, Sampietro T.
J Atheroscler Thromb. 2017 Aug 1;24(8):853-862. doi: 10.5551/jat.37101.
*co-first author

Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages.
Adorni MP, Cipollari E, Favari E, Zanotti I, Zimetti F, Corsini A, Ricci C, Bernini F, Ferri N.
Atherosclerosis. 2017 Jan;256:1-6. doi: 10.1016/j.atherosclerosis.2016.11.019.

Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease.
Zimetti F, Caffarra P, Ronda N, Favari E, Adorni MP, Zanotti I, Bernini F, Barocco F, Spallazzi M, Galimberti D, Ricci C, Ruscica M, Corsini A, Ferri N.
J Alzheimers Dis. 2017;55(1):315-320. doi: 10.3233/JAD-160411.

Lomitapide affects HDL composition and function.
Yahya R, Favari E, Calabresi L, Verhoeven AJM, Zimetti F, Adorni MP, Gomaraschi M, Averna M, Cefalù AB, Bernini F, Sijbrands EJG, Mulder MT, Roeters van Lennep JE.
Atherosclerosis. 2016 Aug;251:15-18. doi: 10.1016/j.atherosclerosis.2016.05.005.

A complex phenotype in a child with familial HDL deficiency due to a novel frameshift mutation in APOA1 gene (apoA-IGuastalla).
Pisciotta L, Vitali C, Favari E, Fossa P, Adorni MP, Leone D, Artom N, Fresa R, Calabresi L, Calandra S, Bertolini S.
J Clin Lipidol. 2015 Nov-Dec;9(6):837-846. doi: 10.1016/j.jacl.2015.09.001.

Cholesterol trafficking-related serum lipoprotein functions in children with cholesteryl ester storage disease.
Zimetti F, Favari E, Cagliero P, Adorni MP, Ronda N, Bonardi R, Gomaraschi M, Calabresi L, Bernini F, Guardamagna O.
Atherosclerosis. 2015 Oct;242(2):443-9. doi: 10.1016/j.atherosclerosis.2015.08.007.

Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome.

Gomaraschi M, Ossoli A, Adorni MP, Damonte E, Niesor E, Veglia F, Franceschini G, Benghozi R, Calabresi L.
Vascul Pharmacol. 2015 Nov;74:80-86. doi: 10.1016/j.vph.2015.06.014.

Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism.
Ronda N, Greco D, Adorni MP, Zimetti F, Favari E, Hjeltnes G, Mikkelsen K, Borghi MO, Favalli EG, Gatti R, Hollan I, Meroni PL, Bernini F.
Arthritis Rheumatol. 2015 May;67(5):1155-64. doi: 10.1002/art.39039.

Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function.
Gomaraschi M, Adorni MP, Banach M, Bernini F, Franceschini G, Calabresi L.
Handb Exp Pharmacol. 2015;224:593-615. doi: 10.1007/978-3-319-09665-0_19.

The natural compound berberine positively affects macrophage functions involved in atherogenesis.
Zimetti F, Adorni MP, Ronda N, Gatti R, Bernini F, Favari E.
Nutr Metab Cardiovasc Dis. 2015 Feb;25(2):195-201. doi: 10.1016/j.numecd.2014.08.004

Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus.
Ronda N, Favari E, Borghi MO, Ingegnoli F, Gerosa M, Chighizola C, Zimetti F, Adorni MP, Bernini F, Meroni PL.
Ann Rheum Dis. 2014 Mar;73(3):609-15. doi: 10.1136/annrheumdis-2012-202914.

Hydrocortisone directly promotes cholesterol accumulation in macrophages.
Greco D, Favari E, Adorni MP, Zimetti F, Gatti R, Bernini F, Ronda N.
Ann Rheum Dis. 2014 Jun;73(6):1274-6. doi: 10.1136/annrheumdis-2013-204806.

Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
Franceschini G, Favari E, Calabresi L, Simonelli S, Bondioli A, Adorni MP, Zimetti F, Gomaraschi M, Coutant K, Rossomanno S, Niesor EJ, Bernini F, Benghozi R.
J Clin Lipidol. 2013 Sep-Oct;7(5):414-22. doi: 10.1016/j.jacl.2013.06.007.

Inflammation impairs eNOS activation by HDL in patients with acute coronary syndrome.
Gomaraschi M, Ossoli A, Favari E, Adorni MP, Sinagra G, Cattin L, Veglia F, Bernini F, Franceschini G, Calabresi L.
Cardiovasc Res. 2013 Oct 1;100(1):36-43. doi: 10.1093/cvr/cvt169.

Rac1 and cholesterol metabolism in macrophage.
Adorni MP, Ronda N, Bernini F, Favari E.
J Cardiovasc Pharmacol. 2013 Nov;62(5):418-24. doi: 10.1097/FJC.0b013e31829dd874. Review.

ABCA1-dependent serum cholesterol efflux capacity inversely correlates with pulse wave velocity in healthy subjects.
Favari E, Ronda N, Adorni MP, Zimetti F, Salvi P, Manfredini M, Bernini F, Borghi C, Cicero AF.
J Lipid Res. 2013 Jan;54(1):238-43. doi: 10.1194/jlr.P030452.

Novel mutations of ABCA1 transporter in patients with Tangier disease and familial HDL deficiency.
Fasano T, Zanoni P, Rabacchi C, Pisciotta L, Favari E, Adorni MP, Deegan PB, Park A, Hlaing T, Feher MD, Jones B, Uzak AS, Kardas F, Dardis A, Sechi A, Bembi B, Minuz P, Bertolini S, Bernini F, Calandra S.
Mol Genet Metab. 2012 Nov;107(3):534-41. doi: 10.1016/j.ymgme.2012.08.005.

Cellular cholesterol efflux and cholesterol loading capacity of serum: effects of LDL-apheresis.
Adorni MP, Zimetti F, Puntoni M, Bigazzi F, Sbrana F, Minichilli F, Bernini F, Ronda N, Favari E, Sampietro T.

J Lipid Res. 2012 May;53(5):984-9. doi: 10.1194/jlr.P024810.

Characterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations of ANGPTL3.
Pisciotta L, Favari E, Magnolo L, Simonelli S, Adorni MP, Sallo R, Fancello T, Zavaroni I, Ardigò D, Bernini F, Calabresi L, Franceschini G, Tarugi P, Calandra S, Bertolini S.
Circ Cardiovasc Genet. 2012 Feb 1;5(1):42-50. doi: 10.1161/CIRCGENETICS.111.960674.

Free cholesterol alters macrophage morphology and mobility by an ABCA1 dependent mechanism.
Adorni MP, Favari E, Ronda N, Granata A, Bellosta S, Arnaboldi L, Corsini A, Gatti R, Bernini F.
Atherosclerosis. 2011 Mar;215(1):70-6. doi: 10.1016/j.atherosclerosis.2010.12.004.

Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1.
Favari E, Calabresi L, Adorni MP, Jessup W, Simonelli S, Franceschini G, Bernini F.
Biochemistry. 2009 Nov 24;48(46):11067-74. doi: 10.1021/bi901564g.

A novel homozygous mutation in CETP gene as a cause of CETP deficiency in a Caucasian kindred.
Calabresi L, Nilsson P, Pinotti E, Gomaraschi M, Favari E, Adorni MP, Bernini F, Sirtori CR, Calandra S, Franceschini G, Tarugi P.
Atherosclerosis. 2009 Aug;205(2):506-11. doi: 10.1016/j.atherosclerosis.2009.01.006.

Functional LCAT is not required for macrophage cholesterol efflux to human serum.
Calabresi L, Favari E, Moleri E, Adorni MP, Pedrelli M, Costa S, Jessup W, Gelissen IC, Kovanen PT, Bernini F, Franceschini G.
Atherosclerosis. 2009 May;204(1):141-6. doi: 10.1016/j.atherosclerosis.2008.08.038.

Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux.
Sankaranarayanan S, Oram JF, Asztalos BF, Vaughan AM, Lund-Katz S, Adorni MP, Phillips MC, Rothblat GH.
J Lipid Res. 2009 Feb;50(2):275-84. doi: 10.1194/jlr.M800362-JLR200.

The roles of different pathways in the release of cholesterol from macrophages.
Adorni MP, Zimetti F, Billheimer JT, Wang N, Rader DJ, Phillips MC, Rothblat GH.
J Lipid Res. 2007 Nov;48(11):2453-62. doi: 10.1194/jlr.M700274-JLR200.

Impaired ATP-binding cassette transporter A1-mediated sterol efflux from oxidized LDL-loaded macrophages.
Favari E, Zimetti F, Bortnick AE, Adorni MP, Zanotti I, Canavesi M, Bernini F.
FEBS Lett. 2005 Dec 5;579(29):6537-42. doi: 10.1016/j.febslet.2005.10.042

<u>Others publications</u>

2019. PCSK9, COLESTEROLO E MALATTIA DI ALZHEIMER: QUALI EVIDENZE DALLA RICERCA DI BASE. [PCSK9, cholesterol and Alzheimer's disease: evidence from basic research].
Maria Pia Adorni, Massimiliano Ruscica, Nicola Ferri, Franco Bernini, Francesca Zimetti
Giornale Italiano dell'Arteriosclerosi 2019;10(4):5-20

2006. Capitolo "Ca antagonisti e modulatori dei canali del potassio"
Trattato di farmacologia e terapia. Basi Farmacologiche e Terapia Cardiovascolare
Casa Editrice UTET, 2006
Franco Bernini, Maria Pia Adorni, Chiara Degirolamo

I hereby authorize the treatment of my personal data as article 13th of Italian law 196/2003

Sincerely,
Maria Pia Adorni